TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Changes in Activity Card Sort (ACS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Subjects Affected With Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Adverse Events by Severity, Seriousness and the Relationship of AE(s) to Treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Appropriate ICD shock at least 14 days post randomization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sustained VT requiring treatment at least 14 days post randomization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Recurrence free rate
Endpoint domain: Mortality/survival
Primary endpoint: rate of seroconversion in HIV-infected patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Post-test probability of celiac disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Femoral quadriceps muscle mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Good clinical outcome defined as modified Rankin Scale 0-2
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change From Baseline in Serum Potassium at Day 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in Serum Potassium at Day 15
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Confirmed and Severe Hyperkalemia
Endpoint domain: Adverse events/effects
Primary endpoint: AUC0-inf of GK Activator (2) and simvastatin acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-6h of plasma glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proximal femoral BMD change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Protocol Recommendations Accepted
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Successful Endotracheal Intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Integrated levels of urinary progestin (Pregnanediol-3-Glururonide or Pd3G)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: change in acne lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: implant insertion torque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: implant stability quotient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Performance on Tests of Hemispatial Neglect and Sustained Attention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Paradoxical excitement response
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Insulin Secretion at Steady-state
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Ratio of Whole Body Glucose Disposal to Plasma Insulin at Steady-state
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Time to PSA Progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Positive Subscale of Positive and Negative Syndrome Scale (PANSS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Behavioral Assessment of Pain Screening Instrument (BAPSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Public Health Questionnaire-9 (PHQ-9)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Hair Counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge assessment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Risk perception assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Self-efficacy assessment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: BP changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in cardiac output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in systemic vascular resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in intracellular and extracellular volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic performance of ULDCT in diagnosis of DPLD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prognostic performance of ULDCT in follow up of DPLD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of immune dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: ICU-acquired infection
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma concentrations of Semuloparin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacodynamic activity (anti-Xa activity) of Semuloparin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Workshop Recruitment Rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Workshop Completion Rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Satisfaction with the workshop
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Median headache score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Family-reported quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Duration of teeth alignment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: occurrence of syncope/presyncope during tilt test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of broad-spectrum antibiotic prescribing
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Safety of intravenous infusion of MSC
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of intravenous infusion of MSC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Any adverse event in adult cohort
Endpoint domain: Adverse events/effects
Primary endpoint: Serious adverse events in adult cohort
Endpoint domain: Adverse events/effects
Primary endpoint: Any adverse event in infant cohort
Endpoint domain: Adverse events/effects
Primary endpoint: Serious adverse events in infant cohort
Endpoint domain: Adverse events/effects
Primary endpoint: Ability to taper off drug while disease remains quiet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Onset of Mood and Anxiety Disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Objective sleep measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in postprandial blood glucose concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Re-bleeding rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: incidence of significant brain tissue oxygen desaturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Adherence (minutes of device use per night)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Apnea-Hypopnea Index (AHI, events/hr)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of Participants Positive for Antidrug Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Local Tolerability
Endpoint domain: Adverse events/effects
Primary endpoint: Change in lexical decision making
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in real-word reading efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Pseudoword reading efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in phonemic decoding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Recruitment of patients
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Tumor-to-background ratio (SPECT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Time to complete expulsion of the ventilation tube
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in left ventricular systolic function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Roland-Morris Disability Questionnaire (RMQ)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Concentration of midazolam, omeprazole, tolbutamide, and 26489112 in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change over time in WOMAC score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression of activated interferon-α receptors (IFNAR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Vessel density of the sublingual microcirculation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histologic analysis of port-site skin biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Gait Analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Learning and coordination impairments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Japanese Orthopaedic Association Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Induction/maintenance of molecular remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of cough
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Disease Free Survival (DFS) Events
Endpoint domain: Mortality/survival
Primary endpoint: Discontinuation of Study Drug Due to an Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Detection of bacterial DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Left Ventricular Ejection Fraction (%LVEF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Light intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lipid Panels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Insomnia Symptom Severity
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in Physical Health
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Response to Hand eczema severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Proportion of patients with Deep Venous Thrombosis (DVT) and/or Pulmonary Embolism (PE) and/or thrombosis at unusual sites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Patient's Assessment of Ankle Pain (VAS)- Absolute Value Decrease on Day 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of the Foot and Ankle Ability Measurement (FAAM), Activity of Daily Living Subscale (ADL) From Baseline to Day 7
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Patient's Assessment of Ankle Pain (VAS)- Percentage Decrease on Day 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum sodium values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma renin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Incidence of Any Grade 3 Solicited Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Neutralizing Antibody Geometric Mean Titer (GMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sensitivity and specificity of WB-MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rate of HCC incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in esophageal mucosal inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Bold signal and connectivity coefficients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: quadriceps and hamstring muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Interspinous gap opening (ISGO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Left paraspinal muscle (LPM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Right paraspinal muscle (RPM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: fatty acid intakes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: carotenoids intakes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: cholesterol in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: shoulder physical activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: 7-day Point Prevalence of Smoking Abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: early organ dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in mean circulating Treg levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Complete blood count (CBC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Complete comprehensive metabolic panel (CMP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Forced expiratory volume in one second / forced vital capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in proportion and trend of safe non-conveyance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of average monthly migraine days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in migraine pain severity and duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of responders (50% reduction in migraine-days and migraine episodes)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Inflammatory Acne Lesion Counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Nifurtimox concentration in breastmilk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nifurtimox concentration in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of TLR4 Signaling Pathway Analytes With a Significant Change in Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of TOPK/PRPK Signaling Pathway Analytes With a Significant Change in Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction of Depression CGI Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Test of Adolescents Social Skills Knowledge (TASSK)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Quality of Play Questionnaire (QPQ)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Chinese version of the School Bullying Experience Questionnaire (C-SBEQ)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: patients' self-reported pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of POV (Postoperative Vomiting)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients Fulfilling ASAS Response Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of laryngospasm
Endpoint domain: Adverse events/effects
Primary endpoint: Magnitude of protection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with ≥50% protection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of sexually transmitted infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Retention, defined as the proportion of follow-up visits
Endpoint domain: Resource use
Primary endpoint: Number of Patients With Dose Limiting Toxicities (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Tolerated Dose (MTD) of Volasertib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With ICA Without Obstructive CAD or Intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Myocardian injury (scarring)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Heart dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: VAS (Visual Analog Scale) evaluation
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Incidence of vertebral re-fracture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percentage Change in IL-2 Production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Diagnostic yield of thoracoscopic biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absence of Atrial Fibrillation (AF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Bleeding rate from gastric varices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Electrical Impedance Myography measurement in arm muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in IIEF Erectile Function Domain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percent reduction in serum urate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of withdrawal for intolerance
Endpoint domain: Adverse events/effects
Primary endpoint: Patient Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hamilton Depressive Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Radiographic Alignment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Goldmann Applanation Tonometry values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: nalbuphine consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Subcutaneous tissue concentrations of TR-700
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in E/Ea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Epidural needle tip position
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: head position tracking accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: head force tracking accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: head position stabilization accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neck force and muscle activation directionality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Propofol and remifentanil dose to maintain BIS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Medication adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Occurrence of any AE related to the study vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of Grade 3 laboratory toxicities related to the study vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of SAEs related to the study vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: End-tidal carbon dioxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: POCD incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Freedom from composite of perioperative death < 30 days and freedom from major adverse limb events (MALE)
Endpoint domain: Mortality/survival